Today announced the initiation of a stage 1 clinical study of ALKS 37.

ALKS 37 is a component of ALKS 36, a combination drug applicant for the treating pain without the medial side effects of constipation. Related StoriesDrug that relieves opioid-induced constipation may help some cancer individuals live longerNew computer-based modeling may help improve outcomes for infants with neonatal abstinence syndromeEgalet announces launch of OXAYDO Tablets and IMPACT-Rx initiativeAccording to IMS Wellness, over 200 million prescriptions were created for opioids in 2007 in the usa.Jones, Ph.D., was appointed Vice President, Biology and Preclinical Development and John H. Van Duzer, Ph.D., was appointed Vice President, Manufacturing and Chemistry. Acetylon is certainly applying its scientific experience to the development of small molecule HDAC inhibitors that build upon the established therapeutic potential of HDAC inhibition with enhanced focus on selectivity. The Company believes that its highly selective HDAC inhibitors may accomplish enhanced clinical utility by reducing or eliminating the debilitating and sometimes life-threatening side effects associated with the current first-generation of nonselective HDAC inhibitors. Simon and John will be applying our drug discovery platform to the creation of extra isoform-selective HDAC inhibitor drug candidates for the treatment of autoimmune, various other and neurodegenerative major illnesses.